基础医学与临床 ›› 2018, Vol. 38 ›› Issue (7): 928-932.

• 研究论文 • 上一篇    下一篇

二甲双胍对肥胖症患者的胰岛素敏感性和胰岛β细胞分泌的影响

张昱1,朱惠娟1,王林杰2,阳洪波2,陈适2,赵宇星1,潘慧1   

  1. 1. 北京协和医院
    2. 中国医学科学院 北京协和医学院 北京协和医院
  • 收稿日期:2018-03-12 修回日期:2018-04-28 出版日期:2018-07-05 发布日期:2018-06-29
  • 通讯作者: 潘慧 E-mail:panhui20111111@163.com
  • 基金资助:
    国家临床重点专科建设项目;国家自然科学基金项目

Effects of metformin on insulin sensitivity and islet beta cell secretion in obesity patients

  • Received:2018-03-12 Revised:2018-04-28 Online:2018-07-05 Published:2018-06-29
  • Supported by:
    the National Key Program of Clinical Science;the National Natural Science Foundation of China

摘要: 目的 探讨肥胖症合并胰岛素抵抗患者口服二甲双胍治疗后胰岛素敏感性和胰岛β细胞分泌功能的变化。方法 选取北京协和医院内分泌科肥胖门诊2012年9月至2016年5月诊断肥胖症合并胰岛素抵抗且严格随诊的患者共42例,年龄为(23.6±6.5)岁,男性11例,女性31例。根据口服75 g葡萄糖耐量试验(OGTT)分为正常糖耐量组(NGT组)19例,糖调节受损组(IGR组)23例,包括空腹血糖受损(IFG)15例和糖耐量低减(IGT)8例。42例患者均采用生活方式干预并口服盐酸二甲双胍500 mg,4次/日治疗,分别于治疗前、治疗3和6个月检查体质量、腰围(WS)、空腹血糖(FPG)、空腹胰岛素(FINS)、计算体质量指数(BMI)、稳态模型(HOMA)公式计算胰岛素抵抗指数(HOMA-IR)和胰岛素分泌指数(HOMA-β)。结果 1)FINS变化:42名患者,治疗3个月FINS较治疗前升高(28.23±10.14 vs 32.25 ±11.99,P<0.05),治疗6个月FINS较服药前降低(P<0.05)。NGT组,治疗3个月FINS较治疗前升高(29.21±10.75 vs 34.05±11.07,P<0.05),2组中治疗6个月FINS较治疗前均降低(P<0.05)。 2)HOMA-IR变化:42例患者,治疗6个月HOMA-IR降至最低(P<0.001)。2组中治疗6个月HOMA-IR均降至最低(P<0.05)。3)HOMA-β变化:42例患者,HOMA-β在治疗3个月最高(P<0.001)。NGT组和IGR组,HOMA-β均在治疗3个月最高(P<0.05)。4)IGR组与NGT组比较:IGR组治疗前HOMA-β低于NGT组治疗前HOMA-β[220.15(155.38,314.71)vs 344.58(280.51,429.26),P<0.05]。结论 口服二甲双胍治疗肥胖症合并胰岛素抵抗患者,其促进β细胞胰岛素分泌的作用较改善外周组织胰岛素敏感性的作用更早出现;治疗3个月内,与糖调节受损患者相比,在糖耐量正常的肥胖症患者中其促进β细胞分泌胰岛素的作用更明显。

关键词: 二甲双胍, 胰岛素敏感性, 胰岛素分泌, 胰岛β细胞

Abstract: Objective To investigate the effects of metformin on insulin sensitivity and secretion in patients with obesity and insulin resistance. Methods This study enrolled the obese patients with insulin resistance who were regular followed-up in Peking Union Medical College Hospital from September 2012 to May 2016 . They were divided into two groups according to their different status of glucose metabolism: normal glucose tolerance(NGT) and impaired glucose regulation(IGR).Life style intervention and metformin were given to all these patients. The antropometric and metabolic data were collected at baseline (before treatment) , 3 months and 6 months after treatment respectively. Results: 42 patients (aged 23.6±6.5 years) including 11 males and 31 females were enrolled. 19 of them were NGT and 23 were IGR ( 8 of IGT and 15 of IFG). Among all these patients, fasting insulin was significantly higher at 3 months after therapy than the baseline(P<0.05).The same situation were observed in Group-NGT(P<0.05). Fasting insulin was significantly lower at 6 months after therapy than at baseline among all patients(P<0.05). HOMA-IR showed no significant difference between the baseline and 3 months after therapy, but significantly higher at baseline and 3 months after therapy than 6 months after therapy(P <0.001). HOMA- beta was significantly(P <0.001)lower at baseline and 6 months after therapy than 3 months after therapy among all patients. HOMA- beta was significantly lower at baseline in Group-IGR than at baseline in Group-NGT (P<0.05). Conclusions The effect of metformin on insulin secretion is earlier than that of improving the insulin sensitivity in patients with obesity and insulin resistance. Metformin is more likely to promote insulin secretion in patients with normal glucose tolerance than those with IGR within 3 months of intervention.

Key words: metformin, Insulin secretion, insulin sensitivity, Islet beta cell

中图分类号: